Development of Potential Anti-Cancer Agents: Diazenes and Derivatives

Drug Development Research

Volumn 61, Issue 2, 2004, Pages 95-100

  Čimbora Zovko, Tamara ^a   Bombek, Sergeja ^b   Košmrlj, Janez ^b   Kovačić, Lidija ^b   Polanc, Slovenko ^b   Katalinić, Ana ^c   Osmak, Maja ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Anti cancer drugs; Diazenes; Drug resistance; Tumor cells

Indexed keywords

2 CHLOROETHYLAMINOCARBONYL DERIVATIVE; ANTINEOPLASTIC AGENT; CARBONYL DERIVATIVE; DIAZENE DERIVATIVE; N (2 CHLOROETHYL) 2 (2,3,4,5,6 PENTAFLUOROPHENYL)DIAZENECARBOXAMIDE; NITROGEN; SB 681; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CALORIMETRY; CANCER CELL; CANCER INHIBITION; CELL GROWTH; CELL SURVIVAL; CHEMICAL BOND; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; GLIOBLASTOMA; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; IC 50; LARYNX CARCINOMA; STRUCTURE ACTIVITY RELATION; UTERINE CERVIX CARCINOMA;

EID: 1542373579     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10336     Document Type: Article

References (25)

1. 4-promoted halogen migration during an electrophilic amination of halogened phenols. Chem Commun 7:1494-1495.
2. Bredel M. 2001. Anticancer drug resistancein primary human barin tumors. Review. Brain Res Rev 35:161-204.
3. Čimbora T, Bombek S, Polanc S, Osmak M. 2003. Methyl 2-(2chlorothylaminocarbonyl)diazenecarboxylate SB-166 inhibits the growth of different tumour cell lines, including drug-resistant sublines. Toxicol In Vitro 17:159-164.
4. Dickinson DA, Forman HJ. 2002. Cellular glutathione and thiols metabolism. Biochem Pharmacol 64:1019-1026.
5. Filomeni G, Rotilio G, Ciriolo MR. 2002. Cell signalling and the glutathione redox system. Biochem Pharmacol 64:1057-1064.
6. Gottesman MM, Fojo T, Bates SE. 2002. Multidrug resistance in cancer: role of ATP-dependent transporter. Review. Nature Rev 2:48-58.
7. Hannun YA. 1997. Apoptosis and dilemma of cancer chemotherapy. Blood 89:1845-1853.
8. Kaufmann SH, Earnshaw WC. 2000. Minireview Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256:42-49.
9. Košmrlj J, Kočevar M, Polanc S. 1996. A mild approach to 1,3,4-oxadiazoles and fused 1,2,4-triazoles. Diazenes as intermediates? Synlett 652-654.
10. Košmrlj J, Kočevar M, Polanc S. 1998. Controlled oxidation of thiols to disulfides by diazenecarboxa mides. J Chem Soc Perkin Trans 1:3917-3919.
11. Locigno R, Castronovo V. 2001. Reduced glutathione system: role in cancer development, prevention and treatment (Review). Int J Oncol 19:221-236.
12. McLellan LI, Wolf CR. 1999. Glutathione and glutathione-dependent enzymes in cancer drug resistance. Drug Resist Updates 2:153-164.
13. Mickisch G, Fajta S, Keilhauer G, Schlike E, Tschada P, Alken P. 1990. Chemosensitivity testing of primary human renal cell carcinoma by tetrazolium based microculture assay (MTT). Urol Res 18:131-136.
14. Moskatelo D, Benjak A, Laketa V, Polane S, Košmrlj J, Osmak M. 2002a. Cytotoxic effect of diazenes on tumour cells in vitro. Chemotherapy 48:36-41.
15. Moskatelo D, Polanc S, Košmrlj J, Vukovic̀ L, Osmak M. 2002b Diazenecarboxamide UP-91, a potential anti-cancer agent, acts by reducing cellular glutathione content. Pharmacol Toxicol 91: 258-263.
16. Mounetou E, Legault J, Lacroix J, Gaudreault R.C. 2001. Antimitotic antitumour agents: synthesis, structure-activity relationships, and biological characterization of NAryl-N′-(2-chloroethyl)ureas as new selective alkylating agents. J Med Chem 44:694-702.
17. Osmak M, Bordukalo T, Jernej B, Košmrlj J, Polanc S. 1999a. Diazene JK-279: potential anti-cancer drug. Anti-Cancer Drugs 10:853-859.
18. Osmak M, Bordukalo T, Košmrlj J, Kvajo M, Marijanovic̀ Z, Eljuga D, Polanc S. 1999b. Diazenes: modificators of tumour cell resistance to cisplatin. Neoplasma 46:201-206.
19. Osmak M, Bordukalo T, Ambriovic Ristov A, Jernej B, Košmrlj J, Polanc S. 2000. Diazenes as potential modificators of drug-resistance in tumour cells. Neoplasma 47:390-395.
20. Osmak M, Eljuga D. 1992. The response of two vincristine resistant human larynx carcinoma cell clones to chemotherapeutic drugs. Radiol Oncol 26:140-144.
21. Osmak M, Eljuga D. 1993. The characterization of two human cervical carcinoma HeLa sublines resistant to cisplatin. Res Exp Med 193:389-396.
22. Panasci L, Xu Z-Y, Bello V, Aloyz R. 2002. The role of DNA repair in nitrogen mustard drug resistance. Anti-Cancer Drugs 13:1-11.
23. Pieters L, Košmrlj J, Lenaršič R, Kočevar M, Polanc S. 2001. Synthesis and cytotoxicity against human cancer cells of novel diazenecarboxamides. Arkivoc 2:U63-U70.
24. Schmitt CA, Lowe SW. 1999. Apoptosis and therapy. J Pathol 187:127-137.
25. Tietze F. 1969. Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 27:502-522.